AMRX - Company ID 0001723128
The table below shows Amneal Pharmaceuticals, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $282.03M | $110.55M | $91.54M | $25.98M | $247.79M | $341.38M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | $741.79M | $662.58M | $638.89M |
| Inventory | $606.30M | $612.45M | $581.38M | $530.74M | $489.39M | $490.65M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $1.91B |
| $1.59B |
| $1.38B |
| $1.41B |
| $1.52B |
| $1.55B |
| Property, plant & equipment | $442.95M | $424.91M | $447.57M | $469.81M | $514.16M | $477.75M |
| Goodwill | $595.47M | $597.44M | $598.63M | $598.85M | $593.02M | $522.81M |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B |
| Accounts payable | - | - | - | $165.98M | $131.08M | $153.14M |
| Total current liabilities | $881.63M | $1.13B | $846.60M | $752.80M | $677.24M | $676.90M |
| Long-term debt | $2.57B | $2.16B | $2.39B | $2.59B | $2.68B | $2.74B |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | -$535.00M | -$607.06M | -$490.18M | -$406.18M | -$276.20M | -$286.82M |
| Total equity | -$70.79M | -$109.27M | $19.78M | $298.42M | $360.34M | $303.27M |